Pfizer presented data Saturday showing its experimental monthly obesity drug has a side-effect profile similar to the weekly injection Wegovy [1].
The results are significant because a once-monthly dosing schedule could reduce the treatment burden for patients compared to current weekly options. If the drug maintains a safety profile comparable to existing GLP-1 therapies while increasing convenience, it could shift the competitive landscape of the weight-loss medication market.
The data comes from mid-stage trials of the experimental treatment developed by Pfizer and its acquired company, Metsera [1]. The company said the results during a public data presentation to evaluate the safety and feasibility of the once-monthly GLP-1 obesity treatment [1].
Currently, the market is dominated by weekly injections that target the GLP-1 receptor to manage weight. By moving to a monthly cadence, Pfizer aims to provide an alternative that may improve patient adherence, a common challenge with chronic obesity management.
While the side-effect profile is reported as similar to Novo Nordisk's Wegovy, the company continues to monitor the long-term efficacy and safety of the monthly dose [1]. The mid-stage results serve as a bridge to larger, late-stage trials required for regulatory approval.
Pfizer has not provided specific numerical breakdowns of the side effects in the public disclosure, but the company said the profile aligns with expectations for this class of medication [1].
“Pfizer presented data showing its experimental monthly obesity drug has a side-effect profile similar to the weekly injection Wegovy.”
The shift from weekly to monthly administration represents a strategic attempt to capture a larger share of the obesity market by prioritizing patient convenience. Because the side-effect profile appears comparable to the established benchmark of Wegovy, the primary hurdle for Pfizer remains proving that the monthly dose maintains the same weight-loss efficacy over time as the more frequent weekly injections.
